126 related articles for article (PubMed ID: 32447808)
1. Poor adherence and persistence to sodium glucose co-transporter 2 inhibitors in real-world settings: Evidence from a systematic review and meta-analysis.
Ofori-Asenso R; Sahle BW; Chin KL; Mazidi M; Ademi Z; De Bruin ML; Liew D
Diabetes Metab Res Rev; 2021 Jan; 37(1):e3350. PubMed ID: 32447808
[TBL] [Abstract][Full Text] [Related]
2. Adherence, Persistence, and Switching Among People Prescribed Sodium Glucose Co-transporter 2 Inhibitors: A Nationwide Retrospective Cohort Study.
Ofori-Asenso R; Liew D; Lalic S; Mazidi M; Magliano DJ; Ademi Z; Bell JS; Ilomaki J
Adv Ther; 2019 Nov; 36(11):3265-3278. PubMed ID: 31482509
[TBL] [Abstract][Full Text] [Related]
3. Real-world adherence, persistence, and in-class switching during use of dipeptidyl peptidase-4 inhibitors: a systematic review and meta-analysis involving 594,138 patients with type 2 diabetes.
Ogundipe O; Mazidi M; Chin KL; Gor D; McGovern A; Sahle BW; Jermendy G; Korhonen MJ; Appiah B; Ademi Z; De Bruin ML; Liew D; Ofori-Asenso R
Acta Diabetol; 2021 Jan; 58(1):39-46. PubMed ID: 32809070
[TBL] [Abstract][Full Text] [Related]
4. Comparing medication persistence among patients with type 2 diabetes using sodium-glucose cotransporter 2 inhibitors or glucagon-like peptide-1 receptor agonists in real-world setting.
Rea F; Ciardullo S; Savaré L; Perseghin G; Corrao G
Diabetes Res Clin Pract; 2021 Oct; 180():109035. PubMed ID: 34487757
[TBL] [Abstract][Full Text] [Related]
5. Meta-analysis of studies examining medication adherence, persistence, and discontinuation of oral antihyperglycemic agents in type 2 diabetes.
Iglay K; Cartier SE; Rosen VM; Zarotsky V; Rajpathak SN; Radican L; Tunceli K
Curr Med Res Opin; 2015; 31(7):1283-96. PubMed ID: 26023805
[TBL] [Abstract][Full Text] [Related]
6. Lower risk of death and cardiovascular events in patients with diabetes initiating glucagon-like peptide-1 receptor agonists or sodium-glucose cotransporter-2 inhibitors: A real-world study in two Italian cohorts.
Baviera M; Genovese S; Lepore V; Colacioppo P; Robusto F; Tettamanti M; D'Ettorre A; Avanzini F; Fortino I; Nicolucci A; Roncaglioni MC; Giorgino F
Diabetes Obes Metab; 2021 Jul; 23(7):1484-1495. PubMed ID: 33606897
[TBL] [Abstract][Full Text] [Related]
7. Sodium-glucose co-transporter 2 inhibitors and cardiovascular outcomes: A systematic review and meta-analysis.
Usman MS; Siddiqi TJ; Memon MM; Khan MS; Rawasia WF; Talha Ayub M; Sreenivasan J; Golzar Y
Eur J Prev Cardiol; 2018 Mar; 25(5):495-502. PubMed ID: 29372664
[TBL] [Abstract][Full Text] [Related]
8. Effects of sodium-glucose co-transporter 2 inhibitors on liver parameters and steatosis: A meta-analysis of randomized clinical trials.
Coelho FDS; Borges-Canha M; von Hafe M; Neves JS; Vale C; Leite AR; Carvalho D; Leite-Moreira A
Diabetes Metab Res Rev; 2021 Sep; 37(6):e3413. PubMed ID: 33010191
[TBL] [Abstract][Full Text] [Related]
9. Effect of SGLT2 inhibitors on cardiovascular, renal and safety outcomes in patients with type 2 diabetes mellitus and chronic kidney disease: A systematic review and meta-analysis.
Toyama T; Neuen BL; Jun M; Ohkuma T; Neal B; Jardine MJ; Heerspink HL; Wong MG; Ninomiya T; Wada T; Perkovic V
Diabetes Obes Metab; 2019 May; 21(5):1237-1250. PubMed ID: 30697905
[TBL] [Abstract][Full Text] [Related]
10. High-dose sodium-glucose co-transporter-2 inhibitors are superior in type 2 diabetes: A meta-analysis of randomized clinical trials.
Shi FH; Li H; Shen L; Fu JJ; Ma J; Gu ZC; Lin HW
Diabetes Obes Metab; 2021 Sep; 23(9):2125-2136. PubMed ID: 34048142
[TBL] [Abstract][Full Text] [Related]
11. Effect of Sodium-Glucose Cotransport-2 Inhibitors on Blood Pressure in People With Type 2 Diabetes Mellitus: A Systematic Review and Meta-Analysis of 43 Randomized Control Trials With 22 528 Patients.
Mazidi M; Rezaie P; Gao HK; Kengne AP
J Am Heart Assoc; 2017 May; 6(6):. PubMed ID: 28546454
[TBL] [Abstract][Full Text] [Related]
12. Comparison of medication adherence and persistence in type 2 diabetes: A systematic review and meta-analysis.
McGovern A; Tippu Z; Hinton W; Munro N; Whyte M; de Lusignan S
Diabetes Obes Metab; 2018 Apr; 20(4):1040-1043. PubMed ID: 29135080
[TBL] [Abstract][Full Text] [Related]
13. Identification of subgroups of patients with type 2 diabetes with differences in renal function preservation, comparing patients receiving sodium-glucose co-transporter-2 inhibitors with those receiving dipeptidyl peptidase-4 inhibitors, using a supervised machine-learning algorithm (PROFILE study): A retrospective analysis of a Japanese commercial medical database.
Zhou FL; Watada H; Tajima Y; Berthelot M; Kang D; Esnault C; Shuto Y; Maegawa H; Koya D
Diabetes Obes Metab; 2019 Aug; 21(8):1925-1934. PubMed ID: 31050099
[TBL] [Abstract][Full Text] [Related]
14. Lack of evidence for a harmful effect of sodium-glucose co-transporter 2 (SGLT2) inhibitors on fracture risk among type 2 diabetes patients: a network and cumulative meta-analysis of randomized controlled trials.
Tang HL; Li DD; Zhang JJ; Hsu YH; Wang TS; Zhai SD; Song YQ
Diabetes Obes Metab; 2016 Dec; 18(12):1199-1206. PubMed ID: 27407013
[TBL] [Abstract][Full Text] [Related]
15. Sodium-Glucose Co-Transporter 2 Inhibitors Compared with Sulfonylureas in Patients with Type 2 Diabetes Inadequately Controlled on Metformin: A Meta-Analysis of Randomized Controlled Trials.
Chen Z; Li G
Clin Drug Investig; 2019 Jun; 39(6):521-531. PubMed ID: 31041606
[TBL] [Abstract][Full Text] [Related]
16. Sodium-glucose co-transporter-2 inhibition and ocular outcomes in patients with type 2 diabetes: A systematic review and meta-analysis.
Li C; Zhou Z; Neuen BL; Yu J; Huang Y; Young T; Li J; Li L; Perkovic V; Jardine MJ; Keay L; Markoulli M; Rosenthal N; Capuano G; Yavin Y; Neal B; Arnott C
Diabetes Obes Metab; 2021 Jan; 23(1):252-257. PubMed ID: 32954617
[TBL] [Abstract][Full Text] [Related]
17. Adherence and persistence in patients with type 2 diabetes mellitus newly initiating canagliflozin, dapagliflozin, dpp-4s, or glp-1s in the United States.
Cai J; Divino V; Burudpakdee C
Curr Med Res Opin; 2017 Jul; 33(7):1317-1328. PubMed ID: 28418262
[TBL] [Abstract][Full Text] [Related]
18. Cardiovascular mortality and morbidity in patients with type 2 diabetes following initiation of sodium-glucose co-transporter-2 inhibitors versus other glucose-lowering drugs (CVD-REAL Nordic): a multinational observational analysis.
Birkeland KI; Jørgensen ME; Carstensen B; Persson F; Gulseth HL; Thuresson M; Fenici P; Nathanson D; Nyström T; Eriksson JW; Bodegård J; Norhammar A
Lancet Diabetes Endocrinol; 2017 Sep; 5(9):709-717. PubMed ID: 28781064
[TBL] [Abstract][Full Text] [Related]
19. Real-World Adherence and Persistence to Direct Oral Anticoagulants in Patients With Atrial Fibrillation: A Systematic Review and Meta-Analysis.
Ozaki AF; Choi AS; Le QT; Ko DT; Han JK; Park SS; Jackevicius CA
Circ Cardiovasc Qual Outcomes; 2020 Mar; 13(3):e005969. PubMed ID: 32148102
[TBL] [Abstract][Full Text] [Related]
20. Sodium-glucose co-transporter-2 inhibitors and the risk of diabetic ketoacidosis in patients with type 2 diabetes: A systematic review and meta-analysis of randomized controlled trials.
Liu J; Li L; Li S; Wang Y; Qin X; Deng K; Liu Y; Zou K; Sun X
Diabetes Obes Metab; 2020 Sep; 22(9):1619-1627. PubMed ID: 32364674
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
